Rheumatoid Arthritis Clinical Trial
Official title:
Humira 40 mg/0.8 mL Syringe for Subcutaneous Injection - Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859)]
NCT number | NCT01163292 |
Other study ID # | P12-069 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 2010 |
Est. completion date | October 2012 |
Verified date | December 2013 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The present survey was conducted to evaluate the effectiveness and safety of treatment with adalimumab during the 52-week period following completion of the treatment period in Study NCT00870467 (M06-859) in participants who continued treatment with adalimumab for 52 weeks.
Status | Completed |
Enrollment | 220 |
Est. completion date | October 2012 |
Est. primary completion date | October 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: - The participants were patients who continued treatment with adalimumab until the end of the treatment period in the NCT00870467(M06-859) study and provided informed consent to participate in the present follow-up survey. Exclusion Criteria: - Participants who used biological agents other than adalimumab after the period of treatment in the NCT00870467(M06-859) study were excluded from the present follow-up study. |
Country | Name | City | State |
---|---|---|---|
Japan | Site Reference ID/Investigator# 54680 | Anjo | |
Japan | Site Reference ID/Investigator# 54677 | Aomori | |
Japan | Site Reference ID/Investigator# 54516 | Chiba | |
Japan | Site Reference ID/Investigator# 54660 | Chiba | |
Japan | Site Reference ID/Investigator# 54683 | Chiba | |
Japan | Site Reference ID/Investigator# 54521 | Fukuoka | |
Japan | Site Reference ID/Investigator# 39854 | Gifu | |
Japan | Site Reference ID/Investigator# 54666 | Hamamatsu | |
Japan | Site Reference ID/Investigator# 54682 | Hiroshima | |
Japan | Site Reference ID/Investigator# 54669 | Hyogo | |
Japan | Site Reference ID/Investigator# 54674 | Hyogo | |
Japan | Site Reference ID/Investigator# 54653 | Ibaraki | |
Japan | Site Reference ID/Investigator# 54670 | Kagoshima | |
Japan | Site Reference ID/Investigator# 54692 | Kagoshima | |
Japan | Site Reference ID/Investigator# 54679 | Kawagoe | |
Japan | Site Reference ID/Investigator# 59580 | Kawagoe | |
Japan | Site Reference ID/Investigator# 54662 | Kawasaki | |
Japan | Site Reference ID/Investigator# 54693 | Kirishima | |
Japan | Site Reference ID/Investigator# 54671 | Kitakyushu | |
Japan | Site Reference ID/Investigator# 54643 | Kumamoto | |
Japan | Site Reference ID/Investigator# 59583 | Kyoto | |
Japan | Site Reference ID/Investigator# 59582 | Maebashi | |
Japan | Site Reference ID/Investigator# 39849 | Matsumoto | |
Japan | Site Reference ID/Investigator# 54520 | Matsuyama | |
Japan | Site Reference ID/Investigator# 54644 | Miyazaki | |
Japan | Site Reference ID/Investigator# 54645 | Morioka | |
Japan | Site Reference ID/Investigator# 54654 | Nagano | |
Japan | Site Reference ID/Investigator# 54656 | Nagaoka | |
Japan | Site Reference ID/Investigator# 63052 | Nagasaki | |
Japan | Site Reference ID/Investigator# 54667 | Nagoya | |
Japan | Site Reference ID/Investigator# 54673 | Nagoya | |
Japan | Site Reference ID/Investigator# 54649 | Nara | |
Japan | Site Reference ID/Investigator# 39844 | Niigata | |
Japan | Site Reference ID/Investigator# 54675 | Oita | |
Japan | Site Reference ID/Investigator# 39847 | Okayama | |
Japan | Site Reference ID/Investigator# 54681 | Okayama | |
Japan | Site Reference ID/Investigator# 39846 | Osaka | |
Japan | Site Reference ID/Investigator# 54518 | Osaka | |
Japan | Site Reference ID/Investigator# 54646 | Rifu | |
Japan | Site Reference ID/Investigator# 54661 | Sagamihara, Kanagawa | |
Japan | Site Reference ID/Investigator# 54514 | Saitama | |
Japan | Site Reference ID/Investigator# 54689 | Saitama | |
Japan | Site Reference ID/Investigator# 25922 | Sapporo | |
Japan | Site Reference ID/Investigator# 39850 | Sapporo | |
Japan | Site Reference ID/Investigator# 54651 | Sapporo | |
Japan | Site Reference ID/Investigator# 54652 | Sapporo | |
Japan | Site Reference ID/Investigator# 54522 | Sasebo | |
Japan | Site Reference ID/Investigator# 54650 | Setouchi | |
Japan | Site Reference ID/Investigator# 39851 | Shimotsuke | |
Japan | Site Reference ID/Investigator# 39845 | Shizuoka | |
Japan | Site Reference ID/Investigator# 54517 | Shizuoka | |
Japan | Site Reference ID/Investigator# 59579 | Takamatsu | |
Japan | Site Reference ID/Investigator# 54655 | Takasaki | |
Japan | Site Reference ID/Investigator# 54519 | Tenri | |
Japan | Site Reference ID/Investigator# 54515 | Tokorozawa | |
Japan | Site Reference ID/Investigator# 39842 | Tokyo | |
Japan | Site Reference ID/Investigator# 39852 | Tokyo | |
Japan | Site Reference ID/Investigator# 39853 | Tokyo | |
Japan | Site Reference ID/Investigator# 54647 | Tokyo | |
Japan | Site Reference ID/Investigator# 54657 | Tokyo | |
Japan | Site Reference ID/Investigator# 54658 | Tokyo | |
Japan | Site Reference ID/Investigator# 54678 | Tokyo | |
Japan | Site Reference ID/Investigator# 54688 | Tokyo | |
Japan | Site Reference ID/Investigator# 59581 | Tokyo | |
Japan | Site Reference ID/Investigator# 54672 | Tomigusuku | |
Japan | Site Reference ID/Investigator# 54648 | Toyama | |
Japan | Site Reference ID/Investigator# 54691 | Toyama | |
Japan | Site Reference ID/Investigator# 54690 | Toyoake | |
Japan | Site Reference ID/Investigator# 54676 | Toyohashi | |
Japan | Site Reference ID/Investigator# 54668 | Tsu | |
Japan | Site Reference ID/Investigator# 39843 | Yokohama | |
Japan | Site Reference ID/Investigator# 54663 | Yokohama | |
Japan | Site Reference ID/Investigator# 54664 | Yokohama | |
Japan | Site Reference ID/Investigator# 54665 | Yokohama | |
Japan | Site Reference ID/Investigator# 54659 | Yotsukaido |
Lead Sponsor | Collaborator |
---|---|
AbbVie (prior sponsor, Abbott) |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disease Activity Score (DAS28) | The Disease Activity Score (DAS28) is a combined index used to measure disease activity in participants with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate (ESR). DAS 28 (ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity. | Weeks 0, 26, and 52 | |
Secondary | Matrix Metalloprotease-3 (MMP-3) | MMP-3 level in serum. Positive = >/= 121.0 ng/mL (male) and 59.7 ng/mL (female) | Weeks 0, 26, and 52 | |
Secondary | Modified Total Sharp Score (mTSS) Change From Week 0 to Week 52 | Modified Total Sharp Score (mTSS) is a method of assessing radiographs used in evaluation of inhibition of joint destruction of disease. Digitized X-rays of hands and feet were obtained, then scored in a blinded manner: for erosion (0 [no damage] to 5 [complete collapse or total destruction of joint]) and for joint space narrowing (0 [no damage] to 4 [complete luxation of joint]). Sum of scores was given as total mTSS (0 [normal] to 380 [maximal disease]). Large positive change in mTSS indicates disease progression; small positive/no change indicates slowing/halting of disease progression. | Week 0 to Week 52 | |
Secondary | Health Assessment Questionnaire Disability Index (HAQ-DI) | Participants assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3) eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Participants assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Negative mean changes from baseline in the disability index of the HAQ-DI indicated improvement. | Weeks 0, 26, and 52 | |
Secondary | Number of Participants With Adverse Events (AEs) | Adverse events (AEs) were collected from week 0 till the end of the study. Please see Adverse Event section below for more details. | Week 0 to Week 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |